Point of Care Diagnostics Market Size, Growth, Trends, Revenue, Demand and Future Outlook

Point of Care Diagnostics Market Size- By Product, By platform, By Sample, By Purchase, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Point of Care Diagnostics Market Size- By Product, By platform, By Sample, By Purchase, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Published: Jan 2025 Report ID: HLCA2502 Pages: 1 - 260 Formats*:     
Category : Healthcare
Point of Care Diagnostics Market Introduction and Overview

According to SPER Market Research, the Global Point of Care Diagnostics Market is estimated to reach USD 134.92 billion by 2034 with a CAGR of 9.61%.

The growth of this market is fueled by the rising incidence of chronic diseases, advancements in point-of-care (PoC) testing, the development of CLIA-waived PoC tests, and the shortage of skilled technicians for conducting laboratory tests. Additionally, the expansion of emerging markets and the growing preference of healthcare professionals for PoC tests over traditional lab tests are anticipated to provide substantial growth opportunities. However, pricing pressures stemming from fluctuations in reimbursements are expected to limit the market's growth.

  • Eli Lilly and F. Hoffman-La Roche Ltd. formed a strategic alliance in March 2023 to develop the latter's Elecsys Amyloid Plasma Panel (EAPP). Since this panel has the ability to expedite patients' journeys from diagnosis to treatment and treatment management, this partnership would be advantageous to both businesses and would address a significant unmet medical need.
  • QIAGEN obtained CE certification for its IVD kit and automated testing platform, NeuMoDx, in October 2023. The company's revenue and market share were positively benefited by this program.
Point of Care Diagnostics Market
By Product: The lateral flow assay segment represented the largest share of the point-of-care diagnostics market.
The point-of-care diagnostics market is categorized by platform into lateral flow assays, immunoassays, microfluidics, dipsticks, and molecular diagnostics. In 2022, the lateral flow assays segment held the largest market share. Lateral flow assays are more cost-effective than conventional laboratory testing methods, and their simplicity makes them ideal for healthcare environments with limited resources, allowing for quick testing of various conditions.

By End User: The home care settings and self-testing segment of the point-of-care diagnostics industry is expected to grow at a significant rate.
The home care setting and self-testing segment is expected to see substantial growth driven by growing awareness of home care and the increasing availability of advanced, user-friendly point-of-care diagnostic products such as blood glucose, cholesterol, and pregnancy tests. Furthermore, the COVID-19 pandemic has boosted the adoption of self-testing products for home care, especially for diagnosing and monitoring infectious diseases.

By Region: North America is expected to be the largest market for point of care diagnostics during the forecast period. Factors include a strong healthcare system, quick adoption of advanced testing products, better medical reimbursement, government support for new product development, and increased user awareness.

Point of Care Diagnostics Market


Market Competitive Landscape
The Global Point of Care Diagnostics Market is highly consolidated. Some of the market players are Abbott, AccuBioTech Co., Ltd, ALPHA LABORATORIES, Anbio Biotechnology Co., Ltd., Becton Dickinson (BD), bioMérieux, Danaher Corporation, EKF Diagnostics Holdings plc., F. Hoffmann-La Roche Ltd., Nova Biomedical, Orasure Technologies, Inc., Siemens Healthcare GmbH, Spectral Medical, Inc., and others.

Scope of the Report:
 Report Metric Details
 Market size available for years 2021-2034
 Base year considered 2024
 Forecast period 2025-2034
 Segments coveredBy Product, By platform, By Sample, By purchase, By End Use.
 Regions covered
North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.
 Companies Covered
Abbott, AccuBioTech Co., Ltd, ALPHA LABORATORIES, Anbio Biotechnology Co., Ltd., Becton Dickinson (BD), bioMérieux, Danaher Corporation, EKF Diagnostics Holdings plc., F. Hoffmann-La Roche Ltd., Nova Biomedical, Orasure Technologies, Inc., Siemens Healthcare GmbH, Spectral Medical, Inc., and others.
Key Topics Covered in the Report:
  • Global Point of Care Diagnostics Market Size (FY’2025-FY’2034)
  • Overview of Global Point of Care Diagnostics Market
  • Segmentation of Global Point of Care Diagnostics Market By Product (Glucose, HIV, Hep C, HPV, Hematology, Pregnancy)
  • Segmentation of Global Point of Care Diagnostics Market By Platform (Microfluidic, Dipstick, RT-PCR, INAAT)
  • Segmentation of Global Point of Care Diagnostics Market By Sample (Blood, Urine)
  • Segmentation of Global Point of Care Diagnostics Market By Purchase (OTC, Rx)
  • Segmentation of Global Point of Care Diagnostics Market By End User (Pharmacy, Hospitals, Home Care)
  • Statistical Snap of Global Point of Care Diagnostics Market
  • Expansion Analysis of Global Point of Care Diagnostics Market
  • Problems and Obstacles in Global Point of Care Diagnostics Market
  • Competitive Landscape in the Global Point of Care Diagnostics Market
  • Details on Current Investment in Global Point of Care Diagnostics Market
  • Competitive Analysis of Global Point of Care Diagnostics Market
  • Prominent Players in the Global Point of Care Diagnostics Market
  • SWOT Analysis of Global Point of Care Diagnostics Market
  • Global Point of Care Diagnostics Market Future Outlook and Projections (FY’2025-FY’2034)
  • Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges

5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces 
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape
6.1. Global Point of Care Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type 
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Point of Care Diagnostics Market

7. Global Point of Care Diagnostics Market, By Product (USD Million) 2025-2034
7.1. Glucose
7.2. HIV
7.3. Hep C
7.4. HPV
7.5. Hematology
7.6. Pregnancy

8. Global Point of Care Diagnostics Market, By Platform (USD Million) 2025-2034
8.1. Microfluidic
8.2. Dipstick
8.3. RT-PCR
8.4. INAAT

9. Global Point of Care Diagnostics Market, By Sample (USD Million) 2025-2034
9.1. Blood
9.2. Urine

10. Global Point of Care Diagnostics Market, By Purchase (USD Million) 2025-2034
10.1. OTC
10.2. Rx

11. Global Point of Care Diagnostics Market, By End User (USD Million) 2025-2034
11.1. Pharmacy
11.2. Hospitals
11.3. Home Care

12. Global Point of Care Diagnostics Market Forecast, 2025-2034 (USD Million)
12.1. Global Point of Care Diagnostics Market Size and Market Share

13. Global Point of Care Diagnostics Market, By Region, 2025-2034 (USD Million)
13.1. Asia-Pacific
13.1.1. Australia
13.1.2. China
13.1.3. India
13.1.4. Japan
13.1.5. South Korea
13.1.6. Rest of Asia-Pacific
13.2. Europe
13.2.1. France
13.2.2. Germany
13.2.3. Italy
13.2.4. Spain
13.2.5. United Kingdom
13.2.6. Rest of Europe
13.3. Middle East and Africa
13.3.1. Kingdom of Saudi Arabia 
13.3.2. United Arab Emirates
13.3.3. Qatar
13.3.4. South Africa
13.3.5. Egypt
13.3.6. Morocco
13.3.7. Nigeria
13.3.8. Rest of Middle-East and Africa
13.4. North America
13.4.1. Canada
13.4.2. Mexico
13.4.3. United States
13.5. Latin America
13.5.1. Argentina
13.5.2. Brazil
13.5.3. Rest of Latin America 

14. Company Profile
14.1. Abbott
14.1.1. Company details
14.1.2. Financial outlook
14.1.3. Product summary 
14.1.4. Recent developments
14.2. AccuBioTech Co., Ltd
14.2.1. Company details
14.2.2. Financial outlook
14.2.3. Product summary 
14.2.4. Recent developments
14.3. ALPHA LABORATORIES
14.3.1. Company details
14.3.2. Financial outlook
14.3.3. Product summary 
14.3.4. Recent developments
14.4. Anbio Biotechnology Co., Ltd.
14.4.1. Company details
14.4.2. Financial outlook
14.4.3. Product summary 
14.4.4. Recent developments
14.5. Becton Dickinson (BD)
14.5.1. Company details
14.5.2. Financial outlook
14.5.3. Product summary 
14.5.4. Recent developments
14.6. bioMérieux
14.6.1. Company details
14.6.2. Financial outlook
14.6.3. Product summary 
14.6.4. Recent developments
14.7. Danaher Corporation
14.7.1. Company details
14.7.2. Financial outlook
14.7.3. Product summary 
14.7.4. Recent developments
14.8. EKF Diagnostics Holdings plc.
14.8.1. Company details
14.8.2. Financial outlook
14.8.3. Product summary 
14.8.4. Recent developments
14.9. F. Hoffmann-La Roche Ltd.
14.9.1. Company details
14.9.2. Financial outlook
14.9.3. Product summary 
14.9.4. Recent developments
14.10. Nova Biomedical
14.10.1. Company details
14.10.2. Financial outlook
14.10.3. Product summary 
14.10.4. Recent developments
14.11. Orasure Technologies, Inc.
14.11.1. Company details
14.11.2. Financial outlook
14.11.3. Product summary 
14.11.4. Recent developments
14.12. Siemens Healthcare GmbH
14.12.1. Company details
14.12.2. Financial outlook
14.12.3. Product summary 
14.12.4. Recent developments
14.13. Spectral Medical, Inc.
14.13.1. Company details
14.13.2. Financial outlook
14.13.3. Product summary 
14.13.4. Recent developments
14.14. Others 

15. Conclusion

16. List of Abbreviations

17. Reference Links

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3


Frequently Asked Questions About This Report
Point of Care Diagnostics Market size is USD 134.92 billion from 2025 to 2034.
Point of Care Diagnostics Market is covered By Product, By platform, By Sample, By purchase, By End Use.
The North America is anticipated to have the highest Market share in the Point of Care Diagnostics Market.
The key players in the Market include Companies Covered Abbott, AccuBioTech Co., Ltd, ALPHA LABORATORIES, Anbio Biotechnology Co., Ltd., Becton Dickinson (BD), bioMérieux, Danaher Corporation, EKF Diagnostics Holdings plc., F. Hoffmann-La Roche Ltd., Nova Biomedical, Orasure Technologies, Inc., Siemens Healthcare GmbH, Spectral Medical, Inc., and others.
The growth of this market is fueled by the rising incidence of chronic diseases, advancements in point-of-care (PoC) testing, the development of CLIA-waived PoC tests, and the shortage of skilled technicians for conducting laboratory tests.
Point of Care Diagnostics Market is projected to reach USD 134.92 billion by 2034, growing at a CAGR of 9.61% during the forecast period.
Point of Care Diagnostics Market grew in Market size from 2025. The Market is expected to reach USD 134.92 billion by 2034, at a CAGR of 9.61% during the forecast period.
Point of Care Diagnostics Market CAGR of 9.61% during the forecast period.
Not able to find what you are looking for? Need customization in the existing report?
Click Here
PLACE AN ORDER
  • 15% off
     
    $ 4250
  • 20% off
             
    $ 5650
  • 25% off
         
    $ 7450
Pre-Purchase Inquiry
SEND AN INQUIRY
NEED CUSTOMIZATION?
Request Customization
CALL OR EMAIL US
US:
India:
Email:
100% Secure Payment

SPER American Express
SPER VISA
SPER Master Card
SPER Mestro
SPER Paypal
SPER CCAvenues

Join Our SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-McKinsey
SPER-Bain
SPER-Max-Healthcare
SPER-DHL
SPER-SIEMENS
SPER-IQVIA
SPER-Pfizer
SPER-LOREAL
SPER-Kankar IMRB
SPER-ITA
SPER-PWC
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-IPSOS
SPER-Heineken

SPER

Market Research

We are the leading, full-service global market research and consulting company.

Certificates
iso-1 iso-1 iso-1 ESOMAR
Secure Payments
SPER Payment Options
Contact HR

 [email protected]

 +91-742-898-5650